Cytokinetics, IncorporatedCytokinetics, IncorporatedCytokinetics, Incorporated

Cytokinetics, Incorporated

No trades
See on Supercharts

Price target

94.880.00 0.00%
The 17 analysts offering 1 year price forecasts for CYTK have a max estimate of — and a min estimate of —.

Analyst rating

Based on 18 analysts giving stock ratings to CYTK in the past 3 months.

EPS

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise

Revenue

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions

CYTK EPS for the last quarter is −1.38 USD despite the estimation of −0.96 USD. In the next quarter EPS is expected to reach −1.14 USD. Track more of Cytokinetics, Incorporated financials and stay on top of what is up with the company.
In the next quarter Cytokinetics, Incorporated revenue is expected to reach ‪912.85 K‬ USD. Check out Cytokinetics, Incorporated revenue and earnings and make informed decisions.
According to analysts, CYTK price target is 94.88 USD with a max estimate of 122.00 USD and a min estimate of 70.00 USD. Check if this forecast comes true in a year, meanwhile keep track of the current situation with CYTK news and stock market news.
We've gathered opinions of 18 analysts rating CYTK stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.